Immunomodulatory effect of *Bifidobacterium breve* on experimental allergic rhinitis in BALB/c mice

JIANJUN REN1, YU ZHAO1, SHI HUANG2, DAN LV1, FENGLING YANG1, LIN LOU1, YONGBO ZHENG1, JIE ZHANG3, SHIXI LIU3, NAN ZHANG1 and CLAUS BACHERT4

1Department of Otorhinolaryngology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041; 2Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610000; 3Upper Airways Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China; 4Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University, 9000 Gent, Belgium

Received December 19, 2017; Accepted May 17, 2018

DOI: 10.3892/etm.2018.6704

Abstract. *Bifidobacterium breve* (*B. breve*) may have a beneficial effect on allergic rhinitis (AR). The aim of the present study was to investigate whether microbial induction of regulatory T cells (Tregs) and adjustment of Th1 and Th2 responses by *B. breve* are associated with protection against allergic inflammation, and to identify a dose-response association in a murine AR model. Ovalbumin (OVA)-sensitized BALB/c mice were orally treated with different doses of *B. breve* [10⁶, 10⁹, 10⁷ and 10⁴ colony forming units (CFU)]. Following nasal challenge with OVA, sneeze frequency, serum OVA-specific immunoglobulin E (IgE) and cytokine concentrations [interleukin (IL)-4, IL-10, IL-13 and interferon-γ (IFN-γ)], splenic percentage of cluster of differentiation (CD)4+CD25+ Tregs, and morphology of the nasal mucosa were examined. Oral treatment with live *B. breve* at doses of 10⁷ CFU or higher alleviated nasal mucosal injury and suppressed sneezing upon repeated administration over a 6-week period. Furthermore, treatment with *B. breve* at these higher doses reduced the concentrations of serum OVA-specific IgE, IL-4 and IL-10, and increased the splenic percentage of CD4+CD25+ Tregs in rhinitic mice compared with those who did not receive probiotics. In contrast, treatment with *B. breve* at a lower dose did not indicate any effect on sneezing frequency or mucosal morphology in this animal model, even though the splenic percentage of CD4+CD25+ Tregs increased and the concentrations of serum OVA-specific IgE and IL-10 declined. *B. breve* exerts its anti-allergic effects by inhibiting type 2 helper T cell immune responses and enhancing CD4+CD25+ Treg activity. Sneezing was also reduced at a dose of 10⁷ CFU or higher. The current study investigated the role of *B. breve* and aided in identifying the optimal dose of *B. breve* administration in the treatment of AR.

Introduction

In recent years, allergic rhinitis (AR) has emerged as a major public health problem worldwide. To date, the underlying immunological mechanisms of AR are not fully understood, as it is a complex multifactorial disorder, involving both innate and adaptive immune responses. AR is classified in the category of type I allergic diseases, which are generally characterized by an elevation in serum immunoglobulin E (IgE) levels (1). This is mediated mainly by type 2 helper T (Th2) cells. These cells synthesize high levels of interleukin (IL)-4, IL-5 and IL-13, which lead to the production of allergen-specific IgE and the release of histamine and leukotriene from mast cells (2). Conversely, type 1 helper T (Th1) cells suppress Th2 immune responses by secreting interferon-γ (IFN-γ) (3). As the influx and differentiation of Th2 cells are important factors in the development and aggravation of AR, previous research has focused on the activation of Th2 cells or modulation of the Th1/Th2 balance to prevent and treat AR: A number of previous studies have investigated the role of activation of regulatory T cells (Tregs) or the induction of immunologic tolerance in the development of allergic diseases (4,5). Tregs can inhibit the differentiation of Th0, their common precursor, into Th2 cells (6,7). Therefore, Tregs may serve an important role in the pathogenesis of AR, controlling immune responses to self and nonself antigens (8). IL-10 is a general inhibitor of proliferative and cytokine responses in T cells, is produced by mononuclear phagocytes, natural killer cells and Th1 and Th2 type lymphocytes (9) and may be the key factor in the immunoregulation. Probiotic bacteria are non-invasive and non-pathogenic living microorganisms, which typically colonize in the intestinal and reproductive system, and, when consumed in adequate numbers, may confer certain health benefits.
on the host. An ameliorating effect has been reported on a range of human diseases including infectious diseases (10), gastrointestinal disorders (11) and allergic diseases (12), and the immunomodulating activity has been demonstrated as an important effect (13). Recent reports (14,15) have documented the role of probiotics in the prevention of allergic disorders, and it is increasingly recognized that probiotics serve a central role not only in Th1/Th2 polarization, but also in inducing the appropriate regulatory mechanisms. Although the specific mechanism is still unclear, reduced serum levels of ovalbumin (OVA)-specific IgE may be associated with enhanced production of Th1 cytokines, decreased synthesis of Th2 cytokines, or both (16). Other reports have identified strain-dependent differences in the ability of probiotics to modulate immune responses. By comparing the anti-allergic treatment effects of four strains of Bifidobacteria and 2 strains of Lactobacilli, Hougee et al (17) demonstrated that oral treatment with B. breve was most effective in reducing allergic responses. The present authors previously compared the anti-allergic qualities of B. breve, Lactobacillus and mixed probiotic (B. breve and Lactobacillus) species by analyzing Th1 and Th2 cytokine levels and the splenic percentage of cluster of differentiation (CD)4+CD25+ Tregs, and confirmed B. breve as the bacterial strain with the most potent anti-allergic treatment effects (unpublished data). In addition, it has been demonstrated that oral treatment with probiotics at doses of 10^7-10^9 colony forming units (CFU) suppresses serum antigen-specific IgE in animal models (8,18). However, there are also reports from both in vitro and clinical studies indicating that a lower dose of B. breve is more effective than higher doses in the treatment of allergic diseases (19,20). Due to these conflicting results, the optimal dose of oral administration of B. breve remains to be determined.

The aim of the present study was to investigate the mechanisms associated with the anti-allergic effects of B. breve in the treatment of AR, and to identify the optimal dose of B. breve administration.

Materials and methods

Animals. A total of 60 female BALB/c mice (age, 6-8 weeks; weight, 20-25 g) purchased from Chengdu Dashuo Laboratory Animal Co, Ltd (Chengdu, China) were acclimatized to the laboratory environment for 1 week prior to the beginning of the experiment. Mice were housed in type III Macrolon cages and provided with standard rodent food and tap water ad libitum. Temperature and humidity were kept constant at 24±1°C and 50%, respectively, with a 12-h light/dark cycle under specific-pathogen-free condition (21). All animals were randomly distributed to 6 treatment groups (n=10 per group; Table I), and all animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals (22) and approved by the Laboratory Animal Ethics Committee of Sichuan University (Chengdu, China).

OVA sensitization and challenge. Mice were sensitized on Day 0 and Day 7 by intraperitoneal injections with phosphate-buffered saline (PBS) or 20 µg OVA grade V (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in 2 mg/0.1 ml Al(OH)_3, gel (Thermo Fisher Scientific, Inc., Waltham, MA, USA) suspended in PBS. Nasal challenge was performed by topical application of PBS or 20 µl OVA solution (10 mg/ml) via nasal drops once daily from Day 14-56. A schematic overview of the study design is presented in Table I and Fig. 1.

Probiotic treatment. The B. breve strain was obtained from the Institute of Biology and Pharmacology of Shanghai Jiao Tong University (Shanghai, China). Live bacteria powder was suspended in 0.2 ml PBS (pH 7.2) at concentrations of 10^9, 10^8, 10^7 and 10^6 CFU prior to administration. B. breve (or PBS) was administered by oral gavage once daily from Day 14 until the mice were sacrificed on Day 56.

Observation of nasal symptoms. Mice were placed in an observation cage, to allow counting of the total number of sneezes by reviewing video records of the animals’ daily activities. Counting commenced immediately following the final intranasal challenge, for a period of 10 min.

Serum OVA-specific IgE levels. ELISA was performed on serum samples to detect IgE levels according to the manufacturer's instructions (439807; BioLegend, Inc., San Diego, CA, USA). Samples were collected following a nasal stimulation test as described and were allowed to clot for ≥30 min prior to centrifugation for 10 min at 1,000 x g (2-8°C). Serum layers were collected separately and stored at -80°C prior to analysis. Serum samples were diluted 1:1-1:6 in standard stock solution to meet the kits standard testing ranges. Absorbance was measured at 450 nm on a Bio-Rad 680 microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Total immunoglobulin levels were calculated with reference to a standard curve using the following equation: Total Ig level=ELISA value (A450) x dilution factor, where A is absorbance. The minimal detection concentration for OVA-specific IgE was 20.7 pg/ml.

Cytokine levels. IL-4, IL-10, IL-13 and IFN-γ levels in serum were determined with Lumines detectors (LUM000; R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's instructions and analyzed using a Lumines100 instrument. Samples were diluted 1:2 in standard stock solution.

Histopathological analysis. Mice were sacrificed on Day 56 to collect nasal tissue for histological observation. The head was removed and the lower jaw, skin and soft tissue were discarded. The skull was decalcified in 10% nitric acid solution for 5 days prior to 10% formalin fixing for 2 days at room temperature and paraffin embedding (12 h, 60°C). Serial sections (4-µm) were cut at the level of middle turbinate and inferior turbinate and stained with hematoxylin for 1-3 min at 25°C and eosin 30-60 sec at 25°C for the detection of infiltrating eosinophils. Sections were reviewed by light microscopy at a magnification, x400.

Spleenic Treg analysis. The spleen was removed and placed on ice, and half of the organ was gently ground prior to filtering through a 40-µm filter to obtain cell suspensions, as detailed previously (7). An eBioscience™ Mouse Regulatory T Cell Staining Kit (88-8115; eBioscience; Thermo Fisher Scientific, Inc.) was used according to the manufacturer's instructions. Approximately 10^6 splenocytes suspended in 1 ml PBS were stained with fluorescein isothiocyanate-labeled anti-mouse...
CD4 (0.625 µg/ml) and phycoerythrin-labeled anti-mouse CD25 antibodies (0.3 µg/ml) provided with the kit for 30 min at 4˚C. According to the manufacture’s instructions permeabilization and fixation (30 min at 4˚C) was performed prior to blocking with anti-mouse CD16/CD32 purified antibody for 15 min at room temperature. The splenocytes were intracellularly stained with APC-labelled anti-mouse forkhead box P3 (Foxp3) antibodies (2.5 µg/ml, provided with the kit) and incubated for 30 min at room temperature. Treg cells were detected by flow cytometry (BD, FACSAria™, Biosciences, Franklin Lakes, NJ, USA) and data were analyzed with FlowJo 7.6 software (Tree Star, Inc., Ashland, OR, USA).

OVA, ovalbumin; CFU, colony forming units.

Table I. Grouping information and probiotics treatment.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Negative control group</th>
<th>Positive control group</th>
<th>10⁶ group</th>
<th>10⁷ group</th>
<th>10⁸ group</th>
<th>10⁹ group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of animals</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Sensitization</td>
<td>PBS</td>
<td>20 µg OVA</td>
<td>20 µg OVA</td>
<td>20 µg OVA</td>
<td>20 µg OVA</td>
<td>20 µg OVA</td>
</tr>
<tr>
<td>Nasal challenge</td>
<td>PBS</td>
<td>200 µg OVA</td>
<td>200 µg OVA</td>
<td>200 µg OVA</td>
<td>200 µg OVA</td>
<td>200 µg OVA</td>
</tr>
<tr>
<td>Probiotic dose</td>
<td>PBS</td>
<td>10⁶ CFU</td>
<td>10⁷ CFU</td>
<td>10⁸ CFU</td>
<td>10⁹ CFU</td>
<td>10¹⁰ CFU</td>
</tr>
</tbody>
</table>

Figure 1. Study design. (A) Graphic abstract for the present study. (B) The experimental protocol. Mice were given probiotics daily from Day 0-56, with OVA-sensitization on Days 0 and 7, and nasal challenge with OVA from Day 14-56. Mice were sacrificed on Day 56 to collect tissue for experimental analysis. OVA, ovalbumin; CFU, colony forming units; IgE, immunoglobulin E; IL, interleukin; IFN, interferon; CD, cluster of differentiation; AR, allergic rhinitis.
Results

Sneeze frequency. The number of sneezes was recorded on Day 56 during a 10-min period starting immediately following the last nasal challenge. As presented in Fig. 2, the sneeze frequency was lower in the negative control group, compared with the positive control group. Oral treatment with B. breve at doses of $10^6$, $10^9$ and $10^7$ CFU significantly reduced the number of sneezes compared with the positive control group, without significant differences among these 3 treatment groups. Treatment with $10^9$ CFU did not have any significant effect on sneezing frequency in comparison with the positive control group.

Serum OVA-specific IgE. Levels of OVA-specific IgE were significantly lower in the negative control group compared with the positive control group, indicating that the OVA sensitization was successful. Oral treatment with all four doses of B. breve significantly reduced OVA-specific IgE, in comparison with the positive control group (Fig. 3).

Impact of B. breve on serum cytokine levels. IL-4 and IL-10 levels were lower in the negative control group and all probiotic treatment groups compared with the positive control group. This reduction was significant for all probiotic groups except for the $10^9$ group in terms of IL-4 levels. There were no significant differences between the $10^9$, $10^7$ and $10^7$ groups. There were no significant differences among the 6 groups in terms of IL-13 and IFN-γ levels (Fig. 4).

Splenic Treg cells. The percentage of CD4+CD25+ Tregs was significantly lower in the positive control group compared with the negative control group. All tested doses of B. breve caused a significant increase in the percentage of CD4+CD25+ Tregs, compared with the positive control group. However, there were no significant differences between different dose groups (Fig. 5). Interestingly, CD4+CD25+Foxp3 Tregs demonstrated no significant difference between groups following repeating experiment several times (data not shown), the reasoning for which was unclear. Therefore, only CD4+CD25+ Tregs were used.

Effects of B. breve treatment on nasal mucosal inflammation. The nasal mucosal epithelium was intact following treatment with B. breve at doses of $10^9$, $10^7$ and $10^7$ CFU, and nasal mucosal congestion was reduced compared with the positive control group; however, the $10^5$ group did not markedly alleviate nasal mucosal edema (Fig. 6).

Discussion

AR evokes an excessive Th2 reaction, leading to high levels of IL-4, IL-5 and IL-13 in serum (2). In the present study, a significant increase of OVA-specific IgE level was detected following OVA sensitization in the positive control group compared with the negative control group, confirming the establishment of sensitization. The present findings, that probiotics are capable of inhibiting OVA-specific IgE production when administered orally following sensitization, are supported by the available literature (23,24). The present results suggest that B. breve intervention reduces the production of OVA-specific IgE and can relieve type I allergy disease in mice. Administration of B. breve at doses of $10^9$, $10^7$ and $10^7$ CFU significantly decreases the OVA-specific IgE levels and sneezing frequency, and nasal mucosal epithelium was protected from local allergic reaction. B. breve administration with $10^5$ CFU significantly decreased the OVA-specific IgE levels, whereas sneezing frequency and nasal mucosal damage were unchanged compared with the positive control.
group, indicating that this lower dose of *B. breve* only slightly relieved the allergic reaction.

In the intestinal immune system, Th1 and Th2 cells influence the production of IgE. Th2 cells secrete IL-5, IL-13 and IL-4, the characteristic factors leading to enhanced IgE production, eosinophilia and atopic disease (25). Several studies have suggested that Th2-cytokines, particularly IL-4 and IL-13, serve a pivotal role in the pathogenesis of allergic diseases by regulating the production of IgE and activation of mast cells (26-28). In contrast, Th1 cells secrete IL-2, IL-12 and IFN-γ, which are responsible for suppression of IgE synthesis as well as the inception of IgE-mediated allergies (29). AR has often been reported to be associated with defective IFN-γ expression (30). The immunoregulatory effects of probiotics have been ascribed to shifting the Th1/Th2 balance towards Th1 mediated immunity, which might inhibit the development of allergies (31), as was confirmed by IgE suppression by *B. breve* in animal allergy models. Despite clear evidence for strong immunomodulatory properties of *B. breve*, the mechanisms underlying these effects are poorly understood. The associated cytokine patterns in OVA-stimulated splenocytes from *Bifidobacterium*-fed mice were highly strain dependent, which indicates that different mechanisms are involved. Reduced serum levels of OVA-specific IgE may be associated with enhanced production of Th1 cytokines, decreased synthesis of Th2 cytokines, or both in some instances, as both Th1 and Th2 cytokines were down regulated (16). The present study demonstrated that IL-4 secretion was significantly lower in the 10⁶, 10⁷ and 10⁸ CFU probiotic groups than in the positive control group, supporting a reduced Th2 response, whereas there was no difference in Th1 representative factors IFN-γ. This suggests that *B. breve* instates Th1/Th2 equilibrium mainly through the inhibition of the Th2 response, without promoting a Th1 response. Previous studies have indicated that the immunoregulatory mechanism of oral probiotics depends on the specific bacterial strain used (32,33). Research on *B. breve* administration demonstrated conflicting results concerning both the mechanisms and treatment effects, and the differences in outcome may be attributed to the use of different probiotic doses of probiotics (17,18). Four different doses of *B. breve* were administered to mice by oral gavage. It was speculated that while different doses of probiotics may indicate varied immunoregulatory capacity, the underlying mechanism is the same.

The spleen is the organ where lymphocytes accept antigen stimulation like the lymph nodes, and give rise to specific immune responses. Tregs are the mediators of immunological tolerance and possess anti-inflammatory capabilities (34). They comprise a diverse group of cells, including CD4+CD25+ T cells, which can suppress antigen-specific responses even in small numbers. Abnormalities in number and function may cause autoimmune diseases (35). In the present study, the ratio of CD4+CD25+ T cells was significantly reduced in the positive control group compared with the negative control group. As CD4+CD25+ T cells can inhibit the differentiation of Th0 cells into Th2 type and the fact that IL-10 is required in the development of Tregs (6,7), it was speculated that inhibition of nasal symptoms by *B. breve* administration may be associated with the induced activity of Tregs. Tolerogenic dendritic cells may be the source of IL-10 for the induction of Tregs (8); therefore,
it has been proposed that probiotics promote the production of IL-10 to induce Tregs. In this regard, a number of studies have confirmed that the symptoms of colitis are significantly relieved by probiotic treatment in IL-10-deficient mice (36). However, Hougee et al (17) have demonstrated that probiotics could not stimulate the secretion of IL-10, but rather caused a reduction. Results from the present study support these latter observations. In the present study, the serum level of IL-10 was...
significantly lower in the *B. breve* treatment groups than that in the positive control group. It has been hypothesized that this decrease in free IL-10 in serum may be caused by an increase of IL-10 receptors (37). This is consistent with the findings of Schabussova et al. (38) who demonstrated that the level of IL-10 mRNA was increased despite the decrease in serum IL-10 following probiotic administration.

It was demonstrated that even when AR mice were treated with a low dose (10^5 CFU) of *B. breve*, the serum OVA-specific IgE level was significantly lower in comparison with the positive control group, indicating that even a low dose has an immunoregulatory effect. Notably, it was demonstrated that in the 10^5 group, IL-10 was reduced and the proportion of CD4+CD25+ Tregs increased, whereas the level of the Th2 cytokine IL-4 did not change. This further supports that a low dose of *B. breve* may have an anti-inflammatory role depending on induction of Treg activity. The immunomodulatory effects of probiotics have been demonstrated in *in vitro* and clinical studies using low doses, whereas negative effects have been demonstrated at high doses (39). In the present study, the sneezing frequency in OVA-sensitized mice were significantly reduced in the higher dose groups, combined with decreased serum IL-4 and OVA-specific IgE levels and increased CD4+CD25+ Tregs in the spleen. In the low dose group, however, probiotics only decreased the levels of OVA-specific IgE and IL-10, and improved splenic CD4+CD25+ Treg levels, whereas there were no significant differences in sneezing frequency, nasal mucosal inflammation and IL-4 levels compared with the positive control group. However, a previous study by the present author (40), which analyzed the effect of different delivery modes (vaginal delivery vs. cesarean delivery) on immune status and nasal symptoms in AR mouse model, presented no significant differences in IL-4, IL-5 and IFN-γ in serum levels. It is suggested that the contradictory results between these two studies may be mainly due to the doses, delivery modes or other mechanism, which requires more in-depth research. Therefore, it is speculated that a low dose of *B. breve* only enhances the function of CD4+CD25+ Tregs and does not increase Th1 response and/or weaken Th2 response. Previous clinical studies (41-43) have demonstrated that probiotics have the potential to improve the quality of life of patients with AR. Their nasal symptoms improved significantly following treatment with oral probiotics. However, the mechanism remains to be elucidated, and further studies should be conducted to explore its therapeutic effects and side effects.

A limitation of the present study is the lack of intestinal immune experiments; experiments regarding the effects of *B. breve* treatment in the composition of immune cells in the guts mucosa were not performed. It was intended to investigate fecal samples to explore the role of *B. breve* in the process of intestinal colonization and intestinal immune system. However, fecal samples were easily contaminated, which may have affected the veracity of results. Future studies should explore the association between intestinal colonization of microbes and AR.

Oral administration of *B. breve* has an anti-allergic effect by inhibiting the Th2 response and inducing the activity of CD4+CD25+ Tregs without evoking the Th1 response. Administration of *B. breve* at higher doses significantly reduced sneezing frequency, combined with decreased serum IL-4 and

Figure 6. Nasal mucosa morphology of ovalbumin-sensitized mice following repeated administration of different doses of *B. breve*. (A) Positive control group; (B) negative control group; (C) 10^10, (D) 10^9, (E) 10^7 and (F) 10^5 CFU-treated groups (original magnification, x200; arrows indicate goblet cells). The nasal mucosal epithelial was intact following treatment with *B. breve* at doses of 10^10, 10^9 and 10^7 CFU, and the nasal mucosal congestion was reduced, compared with the positive control group; however, the 10^5 group did not markedly alleviate edema of the nasal mucosal tissue.
OVA-specific IgE levels and increased CD4+CD25+ Tregs in the spleen, and nasal mucosal epithelium was protected from local allergic reaction. However, a lower dose of B. breve could only slightly relieve the allergic reaction. The current study aimed investigating the role of B. breve in immune response and treatment of AR and provided laboratory animal-based evidence, which may guide probiotic therapies and identifying the optimal dose of B. breve administration.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81170898 and 30801280), the International Scientific and Technological Cooperation Projects of Sichuan Province (grant no. 2016HH0064), the Project of Health and Family Planning Commission (grant no. 150113) to YZ and collaboration between Ghent University (Ghent, Belgium) and Sichuan University (Chengdu, China).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

JR and SH were the principal writers of the manuscript. JR, SH, YZha, DL, FY, CB, NZ, YZhe, JZ, SL, and LL designed this study. JR, SH, FY, DL, JZ, YZhe and LL performed animal experiments and collected the preliminary data. YZha, CB and NZ performed English interpretation and correction of the manuscript. DL, JR, YZha, YZhe and JZ performed the statistical analysis and image production.

Ethics approval and consent to participate

All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals and approved by the Laboratory Animal Ethics Committee of Sichuan University (Chengdu, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


